Hypothesis

Systemic soluble Klotho (sKlotho) doesn't only preserve astrocytic AQP4 polarization; it directly modulates microglial complement receptor 3 (CR3) signaling to gate the sleep‑dependent removal of tagged synapses. During slow‑wave sleep, neuronal activity drives complement C3 deposition on synapses destined for pruning. Microglial CR3 binds iC3b and triggers phagocytosis. We propose that sKlotho suppresses microglial NF‑κB activation, keeping CR3 in a low‑affinity state that permits selective clearance of only excessively tagged synapses. When sKlotho declines with age or renal Klotho loss, microglial NF‑κB rises, CR3 shifts to a high‑affinity phagocytic mode, leading to indiscriminate synaptic elimination during sleep‑associated glymphatic influx. This converts the nightly 'autopsy' from a curated edit into a maladaptive pruning that accelerates network destabilization and cognitive decline.

Novel Mechanistic Insight

1. sKlotho as a microglial checkpoint – sKlotho binds to heparan sulfate proteoglycans on microglia, inhibiting the IKK complex and reducing p65 nuclear translocation. This lowers basal NF‑κB driven transcription of CR3 activators (e.g., TLR2/4) and keeps the receptor in a resting conformation.
2. Sleep‑state gating – The drop in norepinephrine during NREM sleep expands interstitial space, increasing CSF influx and also raising extracellular ATP. ATP‑driven P2X7 receptor activation on microglia normally amplifies NF‑κB; sKlotho dampens this surge, preventing runaway complement uptake.
3. AQP4 independence – Even if AQP4 polarization is intact, excessive microglial phagocytosis can remove synapses faster than they can be replaced, producing a net loss of connectivity despite adequate waste clearance.

Testable Predictions

• Prediction 1: In young mice, intracerebroventricular infusion of sKlotho will reduce microglial p‑p65 levels and decrease CR3 surface density specifically during NREM sleep, without altering AQP4 polarity.
• Prediction 2: Klotho‑deficient mice will show elevated microglial C3‑iC3b binding and increased synaptosome uptake during sleep, measurable by in vivo two‑photon imaging of labeled synapses.
• Prediction 3: Pharmacological blockade of microglial NF‑κB (e.g., with IKK inhibitor BMS‑345541) in Klotho‑low mice will rescue sleep‑dependent synaptic density and improve performance on spatial memory tasks, despite persistent glymphatic deficits.
• Prediction 4: Administering a P2X7 antagonist during sleep will normalize microglial phagocytic activity in Klotho‑deficient animals, uncoupling inflammation from synaptic loss.

Experimental Approach

1. Animal models: Use kidney‑specific Klotho knockout (Ksp‑Cre;Klotho^fl/fl) and aged wild‑type mice.
2. Sleep staging: EEG/EMG to isolate NREM epochs.
3. Readouts:
   • Immunofluorescence for p‑p65 and CR3 on Iba1+ cells.
   • Quantify synaptic puncta (Synapsin‑1/PSD‑95) before and after sleep.
   • In vivo two‑photon microscopy of Thy1‑YFP labeled dendrites to track spine elimination.
   • Glymphatic tracer (CI‑1047) influx to confirm clearance rates.
   • Behavioral assays: Morris water maze, novel object recognition.
4. Interventions: icv sKlotho, IKK inhibitor, P2X7 antagonist delivered via osmotic pump timed to dark phase.
5. Statistical plan: Power analysis (n=8/group) to detect 20% change in spine density; two‑way ANOVA with factors genotype and treatment.

Falsifiability

If sKlotho elevation fails to alter microglial NF‑κB or CR3 dynamics during sleep, or if blocking microglial NF‑κB does not rescue synaptic loss in Klotho‑low mice despite restored glymphatic flow, the hypothesis would be refuted. Conversely, confirmation would position the FGF23‑Klotho axis as a sleep‑state immunoregulator that decides which neural architectures survive the nightly autopsy.